ArticleEuropean heart journal supplements : journal of the European Society of Cardiology2026
How difficult is the diagnosis of heart failure with preserved ejection fraction.
Article in European heart journal supplements : journal of the European Society of Cardiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Heart failure with preserved ejection fraction (HFpEF) is a systemic syndrome driven by inflammation, with a substantial contribution from comorbidities, ageing, lifestyle factors, and genetic predisposition. Heart failure with preserved ejection fraction accounts for ∼50% of hospital admissions for heart failure. Mortality ranges from 15% at 1 year to up to 75% at 5-10 years. This paper provides an overview of HFpEF, spanning epidemiological to therapeutic aspects, with particular focus on diagnostic challenges and strategies to overcome them. The diagnostic pathway leading to HFpEF requires extensive exclusion of potentially confounding conditions. Indeed, the identification of some of these conditions allows for targeted therapies that may improve survival. Diagnostic suspicion begins with the recognition of symptoms and signs of heart failure, followed by the assessment of natriuretic peptides and supported by scoring systems and instrumental investigations performed at rest or during exercise. Heart failure with preserved ejection fraction remains a challenging condition to diagnose due to the lack of uniform definitions in the literature, the presence of symptoms and signs shared with other diseases, and the absence of a universally recognized pathognomonic marker.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.